Treatment approaches for AChR-antibody positive generalized myasthenia gravis in Russia.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, non-interventional, retrospective-prospective single-arm study will enroll about 100 adults with AChR-antibody positive generalized myasthenia gravis across roughly 10 specialized sites in Russia. Clinical data will be collected consecutively from existing medical records and entered into an electronic case report form at seven predefined timepoints, capturing scores such as MG-ADL, QMG, and MGFA class. The study will document diagnostic pathways, first-line and subsequent treatments (including anticholinesterase agents, corticosteroids, immunosuppressants, IVIG, plasmapheresis/plasma filtration, thymectomy, rituximab, and complement C5 inhibitors), rates and reasons for hospitalizations, myasthenic crises, and meningococcal vaccination or prophylactic antibiotic use prior to C5 inhibitor therapy. Enrollment requires written informed consent and excludes patients with ocular-only MG or those currently enrolled in interventional gMG trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults (≥18 years) diagnosed with generalized MG positive for acetylcholine receptor (AChR) antibodies.
2. Provision of signed and dated written informed consent.

Exclusion Criteria:

1. Participants currently enrolled in clinical studies for treatment of gMG.
2. Ocular MG only.

Where it's running

• Research Site
  Kazan', Russia Recruiting
• Research Site
  Moscow, Russia Recruiting
• Research Site
  Novosibirsk, Russia Recruiting
• Research Site
  Rostov-on-Don, Russia Recruiting
• Research Site
  Saint Petersburg, Russia Recruiting
• Research Site
  Samara, Russia Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted Rare-Disease Diagnosis

  A multicenter randomized test to see if an AI diagnostic tool can help doctors make faster, more accurate rare-disease diagnoses for patients with unresolved symptoms.

  Recruiting at 3 sites Peking Union Medical College Hospital · Cangzhou and 11 other locations · NCT07650799

• Impact of efgartigimod on overall disease experience in adults with generalized myasthenia gravis in Italy

  This study looks at real-world use of efgartigimod in adults with generalized myasthenia gravis to see how it affects their daily symptoms and experiences.

  Recruiting at 30 sites argenx · Acquaviva delle Fonti and 29 other locations · NCT07595653

• Socio‑professional inclusion for young people (15–25) with childhood-onset rare genetic disabilities

  This project will try to see what makes it hard for 15–25‑year‑olds with childhood-onset rare genetic conditions to access higher education, internships, or work.

  Recruiting Imagine Institute · Paris, Île-de-France Region · NCT07527624

• ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis

  This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.

  Recruiting at 37 sites argenx · Carlsbad, California and 36 other locations · NCT07294170

• Adding empasiprubart to efgartigimod for AChR-antibody positive generalized myasthenia gravis

  This trial will test whether adding empasiprubart to efgartigimod infusions helps people with AChR-antibody positive generalized myasthenia gravis who have only had a partial response to efgartigimod.

  Recruiting at 33 sites Phase 2 argenx · Carlsbad, California and 32 other locations · NCT07284420

• Zilucoplan for severe gMG flares that require hospitalization.

  This trial will try daily subcutaneous zilucoplan in adults with AChR-positive generalized myasthenia gravis who are hospitalized for severe flares to see if it quickly improves breathing and bulbar symptoms.

  Recruiting Phase 3 Ohio State University · Tampa, Florida and 2 other locations · NCT07215949

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.